Categories: Business

In Response to a Broader FDA Investigation, ByHeart Initiates a Voluntary Recall of Two Batches of Infant Formula

NEW YORK–(BUSINESS WIRE)–ByHeart, a next-generation baby nutrition company, announced today that, out of an abundance of caution, it has chosen to voluntarily recall two batches of ByHeart Whole Nutrition Infant Formula following notification from the U.S. Food and Drug Administration (FDA) of a broader ongoing investigation into a recent outbreak of infant botulism.

- Advertisement -




- Advertisement -

Infant botulism is a rare but potentially fatal illness that presents a serious threat to the health of infants which occurs when Clostridium botulinum spores are ingested and colonize the intestinal tract, producing botulinum neurotoxins in the immature gut of infants. Affected infants can present with some or all of the following signs and symptoms: constipation, poor feeding, ptosis (drooping eyelid), sluggish pupils, low muscle tone, difficulty sucking and swallowing, weak or altered cry, generalized weakness, respiratory difficulty, and possibly respiratory arrest.

- Advertisement -
  • The FDA has an ongoing investigation of infant botulism among babies in the U.S.
  • The FDA has not identified a direct link between any infant formula and these cases and there is no historical precedent of infant formula causing infant botulism.
  • ByHeart is taking the proactive step to remove any potential risk from the market and ensure the highest level of safety for infants.

ByHeart was notified by the FDA on November 7, 2025 of an estimated 83 cases of infant botulism that were reported nationwide since August 2025. Of these, the FDA also noted that 13 infants received ByHeart formula at some point. The FDA has not identified a direct link between any infant formula and these cases and there is no historical precedent of infant formula causing infant botulism. Botulism is extremely uncommon in dairy products or infant formula, and is naturally occurring in environmental sources like soil, select vegetables, and dust.

- Advertisement -

ByHeart adheres to the highest standards of Global and U.S. recommendations for product testing and safety. No ByHeart product has tested positive for any contaminants.

- Advertisement -

“The safety and well-being of every infant who uses our formula is our absolute highest priority,” said Mia Funt, Co-Founder and President. “We take any potential safety concern extremely seriously, and act quickly to protect families. As parents ourselves, we understand the concern this news may raise. This voluntary recall is out of an abundance of caution and comes from our ongoing commitment to transparency and safety for babies and their parents. While no testing by ByHeart or regulatory agencies has confirmed the presence of Clostridium botulinum spores or toxin in any ByHeart product, we are taking this proactive step to remove any potential risk from the market and ensure the highest level of safety for infants.”

- Advertisement -

Product Details for Voluntary Recall:

- Advertisement -

The voluntary recall applies to the following two batches of ByHeart infant formula:

- Advertisement -
  • Batch Code: 251261P2, Use by: 01 Dec 2026
  • Batch Code: 251131P2, Use by: 01 Dec 2026
  • UPC: 5004496800

The batch code and use by can be found on the bottom of the can.

- Advertisement -

No other ByHeart batches are impacted by this voluntary recall.

- Advertisement -

What Consumers Should Do:

- Advertisement -

Consumers who have purchased ByHeart infant formula from the identified batch codes should immediately discontinue use and dispose of the product. If you’ve discarded any formula from the following batches, ByHeart will replace those cans and include two additional cans at no cost.

- Advertisement -

If your infant is experiencing symptoms related to infant botulism, contact your health care provider immediately. To report an illness or adverse event, you can:

- Advertisement -

If any parents have questions please contact our experts at hello@byheart.com. For more information visit byheart.com or call 1 (833) 429 – 4327. We are available 24/7.

- Advertisement -

Contacts

- Advertisement -

Media Contact:
ByHeart Public Relations – press@byheart.com

- Advertisement -
Business Wire

Recent Posts

Biban Forum 2025 Concludes in Riyadh with Agreements Worth Over USD 10.1 Billion and Record Global Participation

RIYADH, Saudi Arabia, Nov. 9, 2025 /PRNewswire/ -- The Small and Medium Enterprises General Authority…

3 hours ago

Quantinuum Selected by DARPA to Advance to Stage B of Quantum Benchmarking Initiative

With the industry's most advanced quantum systems and proven ability to scale, Quantinuum is on…

3 hours ago

Workers at Aimbridge-operated hotels in Los Angeles and Philadelphia strike during event-filled weekend, UNITE HERE reports

Workers at hotels owned by RLJ Lodging Trust on both coasts walk off the job…

4 hours ago

Cango Inc. Releases Letter to Shareholders

HONG KONG, Nov. 6, 2025 /PRNewswire/ -- Cango Inc. (NYSE: CANG) today released a letter…

4 hours ago

Cango Inc. Announces October 2025 Bitcoin Production and Mining Operations Update

HONG KONG, Nov. 3, 2025 /PRNewswire/ -- Cango Inc. (NYSE: CANG) ("Cango" or the "Company")…

4 hours ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

November 08, 2025 17:13 ET  | Source: Intellia Therapeutics, Inc. Deep, stable and durable reductions…

5 hours ago